Celcuity (NASDAQ:CELC) Price Target Raised to $77.00

Celcuity (NASDAQ:CELC) had its target price upped by HC Wainwright from $66.00 to $77.00 in a report released on Wednesday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Celcuity’s FY2026 earnings at ($4.06) EPS, FY2027 earnings at $1.36 EPS, FY2028 earnings at $4.84 EPS and FY2029 earnings at $8.18 EPS.

CELC has been the subject of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, October 8th. Guggenheim initiated coverage on shares of Celcuity in a research note on Monday, September 22nd. They set a “buy” rating for the company. Stifel Nicolaus initiated coverage on shares of Celcuity in a research note on Tuesday, July 1st. They set a “buy” rating and a $30.00 price target for the company. Wall Street Zen upgraded shares of Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday, October 18th. Finally, Needham & Company LLC set a $95.00 price target on shares of Celcuity in a research note on Monday. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.50.

Celcuity Trading Up 0.6%

NASDAQ:CELC opened at $70.97 on Wednesday. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of -20.57 and a beta of 0.70. Celcuity has a 52 week low of $7.57 and a 52 week high of $83.00. The firm has a 50-day moving average price of $53.66 and a two-hundred day moving average price of $29.52.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.14). On average, equities analysts expect that Celcuity will post -2.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director David Dalvey sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the transaction, the director directly owned 125,000 shares of the company’s stock, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the period. Tower Research Capital LLC TRC boosted its holdings in Celcuity by 211.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock valued at $74,000 after purchasing an additional 3,766 shares during the period. Avanza Fonder AB bought a new position in Celcuity in the 3rd quarter valued at $79,000. AlphaQuest LLC boosted its holdings in Celcuity by 176.3% in the 2nd quarter. AlphaQuest LLC now owns 7,087 shares of the company’s stock valued at $95,000 after purchasing an additional 4,522 shares during the period. Finally, Perkins Capital Management Inc. bought a new position in Celcuity in the 1st quarter valued at $115,000. 63.33% of the stock is owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.